This page provides comprehensive information about the topic.
Targeted protein degradation (TPD) leverages the cell's own machinery to eliminate disease-causing proteins, offering a new therapeutic paradigm for neurodegenerative diseases.
- Structure: Two binding domains connected by linker
- Mechanism: Recruits E3 ubiquitin ligase to target protein
- Result: Polyubiquitination and proteasomal degradation
- Advantage: Catalytic activity (substoichiometric)
- Small molecules that induce protein-protein interactions
- Recruit neosubstrates to E3 ligases
- Simpler than bifunctional Protacs
- Example: thalidomide analogs
- Target proteins for autophagy degradation
- S-guanylation modification
- Selective mitophagy possible
- Leverage lysosomal trafficking
- Degrade extracellular proteins
- Receptor-mediated endocytosis
- Target: Hyperphosphorylated tau
- Protac: Tau
- E3 ligase: Cereblon, VHL
- Status: Preclinical promise
- Target: α-syn aggregates
- Protac: α-syn degrader series
- Challenge: Ensuring selective neuronal uptake
- Status: Preclinical
- Target: Mutant huntingtin (HTT)
- Approach: Allele-selective degradation
- Protac: HTT-Protac
- Status: Preclinical
- Target: TDP-43 aggregates in ALS/FTD
- Approach: TDP-43 degrader
- Status: Early development
- Immunomodulatory drug binding
- Brain-penetrant modulators available
- Widely used in TPD
- Well-characterized ligase
- Protac development advanced
- Brain penetration challenge
- Protein-based degrons
- Emerging target
- Cancer applications
- Limited CNS data
- Off-target degradation
- Ubiquitinome effects
- Temporal specificity needed
- Long-term effects unknown
- Immune responses possible
- Cellular stress
- Preclinical validation in mouse models
- AAV delivery approaches
- IND-enabling studies
- Thalidomide derivatives for CNS
- Immunomodulatory approach
- Clinical trials in planning
- Arvinas (multiple programs)
- Kymera Therapeutics
- Nurix Therapeutics
- Ono Pharmaceutical
- Brain-penetrant Protac design
- Allele-selective degraders
- RNA-targeting chimeras (RiboTAC)
- Combination with gene therapy
The study of Targeted Protein Degradation For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.